If you live with endometriosis, you already know the frustrating part. The condition affects more than 11 in 100 American women ages 15 to 44, and about 1 in 10 women of reproductive age worldwide, yet it takes 4 to 11 years on average just to get diagnosed. And once you finally have a name for your pain, the list of approved medicines turns out to be short, and every single one of them works through hormones. There is no cure, either. The World Health Organization says so plainly: treatment aims to control symptoms, not to end the disease.
That does not mean nothing helps. Doctors have real tools and they use them every day. But it explains a lot about the endometriosis experience, and it explains why research in this field matters more than in most. This article walks through what is actually approved today, what researchers are testing right now, and why progress has been slower than it should be.
Looking for treatment options for Endometriosis?
Browse open Endometriosis clinical trials near you! We'll handle the follow-up.
What's approved today
About seven drugs have FDA approval specifically for endometriosis. They all work the same basic way: by lowering the hormones involved in your menstrual cycle, since those hormones are what trigger the misplaced tissue to act up.
The older options are injections and a nasal spray from a drug family called GnRH agonists: Lupron Depot (leuprolide), Zoladex (goserelin), and Synarel (nafarelin). There's also danazol, an older oral hormone drug, and Depo-SubQ Provera 104 (medroxyprogesterone), a progestin injection. These have all been around for decades. They push your body into a low-estrogen state, which calms the tissue down but comes with its own side effects. For example, weight gain is listed as one of the most common side effects of Depo-SubQ Provera 104. So if you've wondered whether endometriosis itself causes weight gain: usually not the disease, sometimes the medication.
Orilissa (elagolix), approved in July 2018, was the first oral option in its class (called a GnRH antagonist) for moderate to severe endometriosis pain, and the first genuinely new treatment in years.
Myfembree (relugolix combined with estradiol and norethindrone acetate) was approved for endometriosis in August 2022. It's a once-daily pill that pairs a GnRH antagonist with small "add-back" doses of hormones, which helps soften the side effects of shutting down your cycle.
That's the full list. Notice what's missing: there's no approved endometriosis treatment that doesn't involve touching your hormones. If you're trying to get pregnant, or you simply can't tolerate hormonal suppression, your options are limited. That gap is exactly where current research is focused.
What about surgery
Surgery, usually laparoscopy, has long played a double role in endometriosis. For years it was the only way to confirm the diagnosis, and it is also used to remove the misplaced tissue. It is not a cure either, and tissue can come back.
Surgical technique is itself an active research topic. Among the studies recruiting right now there are head-to-head comparisons of surgical methods for ovarian endometriomas, for example argon plasma treatment versus cystectomy. Whether and when surgery makes sense is a conversation for you and your doctor, because it depends heavily on your symptoms, your stage, and your plans.
What researchers are studying now
This is the more hopeful part of the story.
HMI-115 is furthest along. It's an antibody that blocks something called the prolactin receptor, which makes it the first potential endometriosis medicine of its kind, and importantly, it's not hormonal. Its developer, Hope Medicine, announced in October 2025 that a global Phase 2 study in endometriosis-related pain was successful, and in 2026 the first patient was dosed in Phase 3 (the last stage before a company can ask the FDA for approval). If it makes it through, it would be the first endometriosis drug that doesn't work by suppressing your cycle.
ENDO-205, from EndoCyclic Therapeutics, is a first-of-its-kind non-hormonal treatment (a peptide). In 2026, the FDA gave it the green light to start testing in people. It's still early, most drugs at this stage don't make it all the way, but it's another sign that non-hormonal options are finally entering trials.
Beyond the drug pipeline, there's a lot happening in academic research. As of August 2026, over 160 endometriosis studies are recruiting on ClinicalTrials.gov, and most of them aren't drug trials at all. They're observational, surgical, imaging, device, or behavioral research. The sponsors are mostly universities and hospitals, including Lille, Louvain, Edinburgh, Fudan, McGill, and Washington University.
What are they studying? Mostly non-invasive ways to diagnose endometriosis, that's the single biggest focus. There's also work on devices for managing flare-ups: Samphire Group is running a 120-person study of remote electrical stimulation as a long-term option. Other studies cover pelvic health physiotherapy, group care models, and long-term questions like cardiovascular risk that went unfunded for decades. One study on our platform is even looking at orthokine therapy, an experimental treatment made from a patient's own blood. It's not an approved endometriosis treatment, which is exactly why it's being tested.
Why endometriosis research takes so long
Three main problems slow this field down.
The placebo problem. Endometriosis pain trials usually track how patients rate their pain day to day, and the placebo response in these studies is notoriously high. Pain naturally rises and falls with the menstrual cycle, so some participants genuinely feel better even on placebo. That means trials have to be bigger and run longer to prove a drug is actually working, which drives up costs and makes companies hesitant to even start. Some researchers are tackling this from a different angle: a 90-person study at BC Women's Hospital and Health Centre is using a more objective pain-measurement technique (called quantitative sensory testing) to look at how the nervous system processes pain in endometriosis, rather than relying on a daily self-reported score.
The diagnosis bottleneck. For a long time, trials required surgical confirmation of endometriosis before someone could enroll. Combine that with a diagnosis that already takes 4 to 11 years on average, and you end up with a small pool of eligible patients, only those who made it all the way through the system. That's why non-invasive diagnostic research matters twice over: it could help patients get answers faster, and it could open up recruitment for every other kind of study. One example shows the scale of this effort: Aspira Women's Health is running a study enrolling 1,200 women to train an AI model to detect endometriosis in patients with chronic pelvic pain, one of the largest studies in the field right now.
The funding gap. Women's health research has been underfunded relative to how many people it affects, for decades. A 2022 paper put it bluntly in its title: "Endometriosis Is Undervalued: A Call to Action." The current research landscape reflects that: most recruiting studies are academic and observational, and only a handful are late-stage drug trials. A condition affecting roughly 190 million women worldwide has produced just seven approved drugs, all working the same basic way, over several decades.
Endometriosis is more than pelvic pain
Doctors are increasingly seeing endometriosis as a condition that affects the whole body, not just the pelvis. It's linked to irritable bowel syndrome, migraines, anxiety, depression, and heart disease. In fact, one study currently recruiting on our platform is focused specifically on that last connection: a Yale University study is enrolling 40 women to look at heart disease risk in people with endometriosis.
What is "endo belly"?
"Endo belly" is what women call the painful abdominal swelling that often shows up around your period. It's not a rare or minor symptom: in a study of 355 women having surgery for suspected endometriosis, 90% reported digestive symptoms, and bloating was the most common one, affecting nearly 83% of them. Another smaller study found bloating in 96% of women with endometriosis, compared to 64% of women without it. Both the WHO and the US Office on Women's Health list bloating as a recognized symptom.
Here's the surprising part: in that same 355-woman study, only about 8% actually had endometriosis tissue on their bowel. So the bloating usually isn't the disease physically sitting in your intestines. That's worth knowing if a doctor tells you your gut symptoms "can't be endometriosis" just because your bowel looks clear on a scan.
One thing endo belly is not: weight gain. Neither the WHO nor the Office on Women's Health lists weight gain as an endometriosis symptom. What is documented is that some of the hormonal medications used to treat endometriosis list weight gain as a side effect. Bloating comes from the disease. Weight change, when it happens, usually comes from the treatment.
What's the difference between endometriosis and adenomyosis?
These two get confused constantly, but the difference really comes down to one thing: where the tissue grows.
- Endometriosis: tissue similar to your uterine lining grows outside the uterus: on the ovaries, fallopian tubes, bowel, or bladder.
- Adenomyosis: that same type of tissue grows into the muscle wall of the uterus itself, which causes the uterus to thicken and enlarge, sometimes to two or three times its normal size.
The symptoms overlap, but they tend to lean in different directions. Adenomyosis is more associated with heavy periods, intense cramps, and an enlarged or tender uterus. Endometriosis tends to cause pelvic pain that spreads beyond the uterus, pain during sex, and fertility challenges.
And yes, you can have both at once, in a study of 1,618 women having endometriosis surgery, about 1 in 5 also turned out to have adenomyosis. If you've been treated for one but your symptoms don't quite match what your doctor described, it might be worth asking about the other.
Can endometriosis shorten your life?
There's some newer research worth knowing about here, though it needs context. A 2024 study in the BMJ, based on a large long-term health study of nurses, found that women with surgically confirmed endometriosis had roughly a one-third higher risk of dying before age 70 compared to women without it, mostly linked to gynecologic cancers. Importantly, the actual (absolute) risk stayed low, this is population-level research, not a prediction about any one person, and it's not connected to your specific stage of the disease. If this worries you, it's a good thing to bring up with your doctor.
Common myths about endometriosis
"It's just a bad period."
Not true. Endometriosis tissue grows outside the uterus, and the condition is linked to health issues well beyond the pelvis. Part of why diagnosis takes so long is that symptoms, including by clinicians, often get dismissed as normal period pain.
"Endometriosis means you can't have children."
Many women with endometriosis do get pregnant. It's true that endometriosis is common among women being evaluated for infertility, so it can make conceiving harder, but it's not a guarantee you won't. In fact, fertility is one of the main reasons researchers are pushing for non-hormonal treatments.
"A hysterectomy cures it."
Removing the uterus doesn't remove tissue that's growing outside the uterus, which is the actual definition of the disease. There's no cure for endometriosis, and both the WHO and the Office on Women's Health say this clearly. Treatment can manage symptoms, but it doesn't cure the condition.
"Stage IV is serious, Stage I is nothing."
Not necessarily. The ASRM (which created the staging system) says the stage doesn't reliably predict how much pain someone experiences. Some women with minimal disease have severe pain, while others with widespread disease have very little.
"It only affects women in their 30s and 40s."
That's when most people get diagnosed, not when the disease actually starts. Symptoms often begin in the teenage years. The gap between when symptoms start and when diagnosis happens is, again, part of the larger diagnostic delay problem.
The four stages, and what care usually looks like
Doctors classify endometriosis with the revised ASRM system, from Stage I to Stage IV. The score behind it adds up where the tissue sits, how deep and how widespread it is, whether there are adhesions (scar tissue binding organs together), and whether there are cysts on the ovaries. A score of 1 to 15 is minimal or mild disease. A score of 16 or higher is moderate or severe. Your stage usually comes out of surgery or imaging, so plenty of women never learn theirs, and many trials use it in their eligibility criteria, which is the practical reason to know it.
Stage I (minimal). A few small implants, little or no scar tissue. Care typically centers on pain management and hormonal medicines, and practice varies a lot from doctor to doctor.
Stage II (mild). More implants, some of them deeper, still limited scar tissue. Usual care looks much like Stage I.
Stage III (moderate). Deeper implants, ovarian cysts on one or both sides, some adhesions. Usual care often combines medicines with a discussion of surgical options.
Stage IV (severe). Many deep implants, large cysts, dense adhesions that can bind organs together. Surgery is more often part of the conversation, sometimes together with fertility planning.
These are descriptions of common practice, not recommendations. Your own plan is between you and your doctor. And it is worth repeating what the ASRM itself says: the stage describes the tissue, not the pain.
How to find an endometriosis study
You can browse recruiting endometriosis studies on our platform, from non-hormonal drug trials to diagnostic, device, and physiotherapy studies. A few examples show the range: an AI-based diagnostic study from Aspira Women's Health aimed at detecting endometriosis without surgery, a device trial testing remote electrical stimulation for managing flare-ups, and a pelvic health physiotherapy study looking at improving access to that kind of care.
The application takes about 5 minutes: you answer basic questions about your diagnosis and symptoms, and the study team contacts you if you may qualify. Applying doesn't commit you to anything, and every detail is explained during informed consent before you decide.
Common questions
What is endometriosis, in simple terms? Endometriosis is a condition where womb-lining-like tissue turns up in places it does not belong, such as the ovaries or the fallopian tubes. It still answers to the monthly hormone cycle, so it swells and bleeds with nowhere to drain, and that causes pain and scarring over the years. Around the world roughly one woman in every ten of childbearing age lives with it, and most wait years before anyone puts a name to it.
Is there a non-hormonal treatment approved for endometriosis? Not yet. All roughly seven FDA approved endometriosis drugs work through hormones. The first non-hormonal candidates, like the antibody HMI-115, are currently in clinical trials, with HMI-115 now in Phase 3.
Is endometriosis genetic? Partly. Twin studies put the genetic contribution at about half of the risk, and your risk is higher if your mother, sister, or aunt has it. There is no genetic test for endometriosis, and a family history does not mean you will develop it.
What is orthokine therapy for endometriosis? It is an experimental approach using autologous conditioned serum, made from the patient's own blood. It is not FDA approved for endometriosis and is being evaluated in a clinical trial listed on our platform.
How is endometriosis diagnosed? For years the only way to confirm it was laparoscopy, a small surgery. That is part of why the average delay from first symptoms to diagnosis runs 4 to 11 years. Doctors also use pelvic exams and imaging like ultrasound, but those can miss smaller growths. Researchers are now working on ways to diagnose endometriosis without surgery, and some of those studies are recruiting on this page.
Can you get pregnant with endometriosis? Yes, many women with endometriosis do get pregnant. It can be harder, though. Endometriosis turns up in a large share of women who get evaluated for infertility. If you are trying to conceive, that is worth a conversation with your doctor, and it is also one reason researchers are working on medicines that do not suppress hormones.
See endometriosis clinical trials recruiting now
Browse endometriosis clinical trials and apply in about 5 minutes.